Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReShape starts gastric balloon study

This article was originally published in Clinica

Executive Summary

ReShape Medical (San Clemente, California) has begun a US trial of its gastric balloon device under an Investigational Device Exemption (IDE). The trial will assess the safety and effectiveness of the non-surgical, dual-balloon device in aiding weight loss. ReShape Balloons occupy space in the stomach to reduce its capacity for food. The balloons remain in place for six months and are then removed. They are designed for overweight patients who can’t or won’t undergo surgery. The placement procedure does not involve general anaesthesia and takes around 15 minutes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel